.Charles Baum, M.D., Ph.D., that supervised Mirati Therapies' $ 5.8 billion purchase to Bristol Myers Squibb in 2015, is actually taking the controls of youthful biotech Terremoto Biosciences.Baum's "significant knowledge in medicine advancement, as well as established track record in advancing high-impact medications, will certainly contribute," outbound CEO Peter Thompson, M.D., said in a July 25 launch. Thompson will certainly retain his seat as panel chairperson..Baum, an experienced physician-scientist, was actually the founder, president and also chief executive officer of oncology-focused Mirati. Prior to that, he assisted build cancer drugs at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will certainly serve as CEO at Terremoto, a firm creating tiny particles to target disease-causing proteins-- like those located in harmful lump tissues-- making use of covalent bonds. Existing therapies that utilize covalent connections primarily target the amino acid cysteine. However, of the twenty amino acids that compose healthy proteins, cysteine is the least common. Terremoto is actually instead targeting some of the important amino acids, lysine, which is actually found in nearly all healthy proteins.Through targeting amino acid lysine and also various other amino acids, Terremoto intends to treat previously undruggable diseases and also develop first-in-class medications..The biotech, based in South San Francisco, increased $75 million in set A backing in 2022. A little bit of much more than a year eventually, the biotech greater than increased that number in a $175 million collection B.